J&J COVID-19 vaccine is 72% effective in the US, 66% overall in large trial

Johnson & Johnson on Friday said its single-dose vaccine was 72% effective in preventing COVID-19 in the United States but a lower rate of 66% was observed globally in the large trial conducted across three continents and against multiple variants.

That level of prevention "will potentially protect hundreds of millions of people from serious and fatal outcomes of COVID-19," Dr. Paul Stoffels, J&J's chief scientific officer, said in a statement. "What we are learning is there is different efficacy in different parts of the world," Stoffels said in a telephone interview.

There were no serious adverse events among those who received the shot, the company said. Full results will be published in a peer-reviewed journal. The US vaccination program got off to a slow start in December and has accelerated to around 1 million shots per day nationwide.

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Regeneron says its COVID-19 antibody cocktail helps prevent symptomatic COVID-19New Phase 3 trial data finds a single shot of Regeneron's COVID-19 antibody cocktail was able to prevent symptomatic COVID-19 among people exposed to the virus, the company said. investing with maria D bate was the best thing that have ever happened to me cause I ear u p to $5000 with $400 through forex trading she's the best I know of , after I was scammed , thanks very much mam . well if you are interested click and message her 👇👇👇 mariadbates2
Source: CNN Philippines - 🏆 13. / 63 Read more »